Development of bicistronic plasmids and fusion proteins for clinical translation of tumor immune reprogramming.
Saved in:
| Title: | Development of bicistronic plasmids and fusion proteins for clinical translation of tumor immune reprogramming. |
|---|---|
| Authors: | Yang J; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA., Chen SS; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA., Idnani E; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA., Shannon SR; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA., Luly K; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA., Fabilane CS; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA., Wilson DS; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA., Spangler JB; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.; Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Department of Molecular Microbiology & Immunology, Johns Hopkins University School of Public Health, Baltimore, MD 21205, USA., Tzeng SY; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA., Green JJ; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Translational ImmunoEngineering Center, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.; Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.; Department of Materials Science & Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.; Institute for NanoBioTechnology and the Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD 21231, USA. |
| Source: | Molecular therapy. Advances [Mol Ther Adv] 2026 Feb 28; Vol. 34 (2), pp. 201708. Date of Electronic Publication: 2026 Feb 28 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Country of Publication: United States NLM ID: 9919257804006676 Publication Model: eCollection Cited Medium: Print ISSN: 3117-387X (Print) Linking ISSN: 3117387X NLM ISO Abbreviation: Mol Ther Adv Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
